Title:
MODULATION OF EXPRESSION OF TH1 TYPE /TH2 TYPE CYTOKININ BY RIBAVIRIN AND RIBAVIRIN ANALOGUE IN ACTIVATED T LYMPHOCYTE
Document Type and Number:
Japanese Patent JP2004035537
Kind Code:
A
Abstract:
To provide a use of ribavirin in the production of a medicine for treating diseases, useful as an immuno-modulation treating agent.
The ribavirin is administered to a patient within the range of a dosage effective for the modulation of expression of a lymphokine in an activated T cell. Especially, the ribavirin is used for inhibiting the Th2-mediated T cell response and accelerating the Th1-mediated T cell response. In other aspect of this invention, ≥1 kind of the ribavirin analogs are administered to a patient within the range of the total dosage effective for the modulation of expression of the lymphokine in the activated T cell. These ribavirin analogs can be used for inhibiting or accelerating the Th1 or Th2-mediated T cell response.
Inventors:
TAM ROBERT
RAMASAMY KANDASAMY
AVERETT DEVRON
RAMASAMY KANDASAMY
AVERETT DEVRON
Application Number:
JP2003033677A
Publication Date:
February 05, 2004
Filing Date:
February 12, 2003
Export Citation:
Assignee:
ICN PHARMACEUTICALS
International Classes:
C07H19/056; A61K31/7056; A61K38/21; A61P31/14; A61P33/02; A61P33/10; A61P37/02; A61P37/04; A61P37/08; A61P43/00; C07H19/052; C07H19/24; (IPC1-7): A61K31/7056; A61P31/14; A61P33/10; A61P37/02; A61P37/04; A61P37/08; A61P43/00; C07H19/056
Attorney, Agent or Firm:
Yoshio Kawaguchi
Makoto Ono
Makoto Ono